



Domain Therapeutics to participate at premier investor and healthcare conferences

- *Dr. Anthony Johnson, President and Chief Executive Officer of Domain Therapeutics, and Sean MacDonald, Chief Business Officer to engage in key industry events in Q2 2024*
- *Domain's leadership will provide a corporate overview including advancements of key drug candidates in immuno-oncology: [DT-9081](#) currently in Phase I ascending dose, as well as [DT-7012](#) and [DT-9045](#) in IND-enabling studies*

Strasbourg, France – Montreal, Canada - Boston, United States, April 2, 2024 – Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:

[Bloom Burton & Co. Healthcare Investor Conference](#) – April 16-17

Location: Metro Toronto Convention Centre (North Building), Toronto, Canada

- Presentation slot: **Wednesday, April 17, 3:30 PM ET**, Room 104 A

[LSX World Congress](#) – April 29-30

Location: Business Design Centre, London, UK

[BioEquity Europe](#) – May 12-14

Location: Kursaal Elkargunea Center, San Sebastián, Spain

- Presentation slot: to be announced at a later date

The portfolio currently boasts the following novel drug candidates in the rapidly evolving cancer field of resistance in the tumor micro-environment:

- **DT-7012**, a best-in-class Treg-depleting anti-CCR8 monoclonal antibody
- **DT-9045**, a first-in-class, PAR2 biased ligand Negative Allosteric Modulator, small molecule
- **DT-9081**, an EP4R antagonist program, small molecule currently in Phase I ascending dose study

-ENDS-

For more information or to schedule a meeting with Dr. Tony Johnson, please contact:

ICR Consilium

Amber Fennell, Namrata Taak, Andrew Stern

Email: DomainTherapeutics@consilium-comms.com

Tel: +44 (0)20 3709 5813

Yucatan (for French media)

Annie-Florence Loyer

Email: AFloyer@yucatan.fr

Tel: +33 (0)6.88.20.35.59

About Domain Therapeutics

Domain Therapeutics, a global clinical-stage biopharmaceutical company, is developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As the leading GPCRs immuno-oncology company, Domain aims to beat resistance to immune modulation within the tumor microenvironment by unveiling therapeutic potential of GPCRs to defeat cancer. Two decades of solid GPCR expertise, validated through multiple pharma partnerships across various therapeutic areas and associated to a world-class drug discovery platform, enable the Company to deepen the understanding of cancer biology and deliver the next generation of immunotherapies to patients.

Domain's proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain's proprietary cross-validation drug discovery and development platform.

Since 2022, the Company raised €51m (\$55m) in series A to progress preclinical and clinical development of its high-value drug candidates to address GPCR-mediated immunosuppression. Domain is supported by leading international venture capital firms from Europe (3B Future Health Fund, Seventure, Schroders, Omnes, Turenne, Theodorus), Asia (Panacea and Viva) and North America (CTI Life Science, adMare).

For more information, please visit: www.domaintherapeutics.com